The US Food and Drug Administration approved PLUVICTO for the treatment of PSMA-positive metastatic hormone-sensitive prostate cancer, which is expected to promote the drug as a new standard treatment for metastatic prostate cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.